Contributions to Hypertension With Androgen Deprivation Therapy

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 20, 2023

Primary Completion Date

July 16, 2025

Study Completion Date

July 16, 2025

Conditions

Androgen Deprivation TherapyProstate CancerHypertensionAutonomic DysfunctionRenal Disease

Interventions

DRUG

Gonadotropin Releasing Hormone Agonists (GNRH)

8 weeks of GnRH agonist

DRUG

Androgen receptor (AR) inhibitor

2 weeks of AR Inhibitor

DRUG

Placebo

Placebo tablet and injection

Trial Locations (1)

UCHealth University of Colorado Hospital, Aurora

All Listed Sponsors

lead

University of Colorado, Denver

OTHER

NCT05700903 - Contributions to Hypertension With Androgen Deprivation Therapy | Biotech Hunter | Biotech Hunter